Introduction:
Last Updated 17 June 2010Lower urinary tract symptoms (LUTS) suggestive of benign
prostatic hyperplasia (BPH) affect 63 million men aged 50 or older worldwide.
Demographic trends suggest an increase in the prevalent LUTS and BPH
populations as a result of aging populations in the major pharmaceutical
markets we cover (United States, France, Germany, Italy, Spain, United Kingdom,
and Japan). Therapies for LUTS and BPH are very effective, but opportunity
remains for therapies that can increase patient adherence to medications. Also,
BPH is a progressive disease, and new therapies are needed that can stop
disease progression and the need for surgery.
Questions Answered in This Report:
*
We forecast the launch of several injectable therapies during
our forecast period.
For which patients will these therapies be appropriate?
How will they be positioned in physicians’ treatment algorithms? How will they perform
commercially, and which agent(s) will outperform others and why?
*
Fixed-dose combinations, such as tamsulosin/dutasteride
(GlaxoSmithKline’s Jalyn/Duodart/Flodart/Combodart), address an important unmet need in the BPH/LUTS
market: increasing patient compliance.
What is the evidence that this
combination is clinically useful? What other therapies may increase compliance?
How will therapies that increase compliance affect the market as a whole?
*
Many men suffering from BPH also suffer from comorbid erectile
dysfunction and/or hypertension.
How many men diagnosed with BPH also suffer
from these comorbidities? How can drug developers use this information to
target key subpopulations?
*
Thought-leading urologists tell us that they are treating
increasing numbers of BPH/LUTS patients with anticholinergic therapies, despite
earlier concerns regarding the increased risk of acute urinary retention
associated with these therapies.
How extensive is this trend, and how will
it affect BPH/LUTS drug sales over the study period? What other changes in
medical practice will affect future drug sales?Scope:
Markets covered: United
States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 17 country-specific interviews with
thought-leading urologists and primary care physicians/general practitioners.
Epidemiology: Prevalent cases of moderate to severe male
LUTS, prevalent cases of BPH with comorbid erectile dysfunction and
hypertension.
Population segments in market forecast: Moderate to
severe male LUTS.
Emerging therapies: Phase II: 2 drugs; Phase III: 2
drugs; preregistration: 0 drugs; registered: 1 drug. Coverage of 3 select preclinical and Phase I products.
Market forecast features: We forecast sales of all
agents to treat male LUTS suggestive of BPH through 2018.
Alternative market scenarios: Tadalafil (Eli Lilly’s
Cialis) achieves favorable reimbursement for BPH in the major markets.